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A B S T R A C T
Given the hazardous nature of many materials and substances, ocular toxicity testing is required to
evaluate the dangers associated with these substances after their exposure to the eye. Historically, animal
tests such as the Draize test were exclusively used to determine the level of ocular toxicity by applying a
test substance to a live rabbit’s eye and evaluating the biological response. In recent years, legislation in
many developed countries has been introduced to try to reduce animal testing and promote alternative
techniques. These techniques include ex vivo tests on deceased animal tissue, computational models that
use algorithms to apply existing data to new chemicals and in vitro assays based on two dimensional (2D)
and three dimensional (3D) cell culture models. Here we provide a comprehensive overview of the latest
advances in ocular toxicity testing techniques, and discuss the regulatory framework used to evaluate
their suitability.
ã 2014 The Authors. Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The location, physiological structure and sensitivity of the
ocular surface predispose it to exposure from a variety of
potentially hazardous environmental conditions and substances
on a daily basis. Many different materials and chemicals can result
in damage to the cornea that may vary from irritation and
inflammation causing mild discomfort to tissue corrosion resulting
in irreversible blindness. These include household, industrial,
agricultural and military products, cosmetics, toiletries and may
even include certain ocular drugs and pharmaceuticals if
incorrectly administered (Wilhelmus, 2001). While exposure to
such substances may be incidental, accidental or intentional
(Vinardell and Mitjans, 2008), most ocular incidents involve
accidental exposure either in the workplace or at home via
splashing with concentrated solutions, such as bleach or
detergents, followed by rapid washing with water or removal
via lacrimation (Shaw et al., 1991). To reduce the risk of exposure to
dangerous substances all manufactured consumer products and
their ingredients must be tested and their eye irritation potential
assessed so that the public can be assured of their safety, or warned
of the associated dangers. Eye toxicity tests are therefore required
to ensure that the risks associated with products meet suitable
safety criteria and are clearly labeled.
Historically, as toxicology testing has become more common, its
reliance upon animal use has increased. This has primarily been due
to the absence of more sophisticated assessment techniques and the
low status of animals in society (Stephens and Mak, 2013). Ethical
reconsideration of animal use for toxicology studies was driven by
the emergence of the animal rights movement in the 1950s
(Stephens and Mak, 2013) and its criticism of animal experimenta-
tion, in particular the use of Draize testing for cosmetics testing. In
1959, Russell and Burch performed a study based upon the
philosophical concept of humanity, in which they observed that
some biological experiments could be classed as “inhumane” based
upon the levels of pain, distress and lasting harm experienced by the
test animals (Russell et al., 1959). Their research provided the
systematic basis of the 3R’s: Replace, Reduce and Refine the use of
sentient beings in experimental biology. This led to a general
expansion of funding sources for ex vivo and in vitro alternative
methods, to reduce the dependency on live animal testing, whilst
also creating a political climate whereby alternative procedures
were incorporated into federal and government legislation
(Stephens and Mak, 2013). In this review, we will provide an
overview of established and newly developed ocular toxicity tests
and discuss their advantages and potential limitations.
2. Draize testing
Live animals have been used to assess and evaluate potentially
harmful products to the eyes since the 18th century (Wilhelmus,
2001).Theinternationalstandardassayforacuteoculartoxicity isthe
rabbit in vivo Draize eye test (Draize et al., 1944) which was
developed in the 1940s by the Food and Drugs Administration (FDA)in response to new laws implemented following permanent eye
injuries occurring due to cosmetics use in the 1930s (Calabrese,
1987). Draizetestingis agovernmentendorsed protocolacceptedby
the Organization for Economic Co-operation and Countries Devel-
opment (OECD, test guidance [TG] 405) (Huhtala et al., 2008; OECD,
2012b). New Zealand white (NZW) rabbits are most commonly used
as they have large eyes with a well described anatomy and
physiology, are easy to handle, readily available and are relatively
inexpensive (Wilhelmus, 2001). The procedure involves the
application of 0.1 ml (or 0.1 g solid) test substance onto the cornea
and conjunctival sac of one eye of a conscious rabbit for up to 72 h
while the other eye serves as an untreated control (Draize et al.,
1944). The original Draize protocol used at least six rabbits per test,
butthiswasreducedtothreeanimalsorasingleanimalwhenserious
ocular damage is expected, with those with severe lesions being
humanely euthanized. The latest Draize test guidelines include the
application and delivery of analgesics and anesthetics (OECD,
2012b) to reduce animal pain and suffering. Rabbits are observed at
selected intervals for up to 21 days for signs of irritation including
redness, swelling, cloudiness, edema, hemorrhage, discharge and
blindness (Huhtala et al., 2008). In cases where severe eye irritation
or pain is observed, it is recommended that the animals are
euthanized or removed from the study prior to the 21 day time point
(OECD,2012b).Theobserveddegreeof irritancyallowsforchemicals
to be classified, based on subjective scoring of the effect on the
cornea, conjunctiva and iris, ranging from non-irritating to severely
irritating. Infact,Draizetestingis theonlytestformallyacceptedand
validated to assess the full range of irritation severity. Both
irreversible and reversible ocular effects can be identified using
this test (Barile, 2010). Eye irritation was traditionally summarized
as a “maximum average score” (MAS) which is an average value
primarily focused on corneal injury, for individual animals at the
time of scoring (Huhtala et al., 2008). However, many countries had
theirownscoringsystems,whichalthoughsimilar intheirapproach,
led to multiple classifications, labels, and data sheets for the same
chemical, dependent upon which country the chemical was been
marketed in. In response to this, and as a means of replacing the
numerous different classification systems, with a single controlled
andunifiedclassificationsystem,theUnitedNations(UN)developed
the current internationally agreed, standard scoring system, known
astheGloballyHarmonizedSystem(GHS),alsoknownasthe“purple
book” (UN, 2013). The GHS utilizes pictograms, signal words, hazard
and precautionary statements, and safety data sheets according to
standardized levels of physical, health and environmental hazards.
The GHS is based upon averaged single tissue observations which
can account for the reversibility of the observed chemical effects
(Eskes et al., 2005). With regards to eye irritation, there are two
primary categories. Substances which cause serious irreversible (up
to21days)damage/destructiontothecornea, irisand/orconjunctiva
are Category 1; substances which cause reversible (within 21 days)
irritation including corneal opacity, iritis, redness or chemosis are
Category2.Category2chemicals canbesplit intotwosubcategories:
2A, irritating to eyes, chemicals which cause reversible irritation to
eyes within 21 days; and 2B, mildly irritating to eyes, chemicals
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chemicals are assigned a GHS No Category classification. The
categories are assigned based on calculations of a mean score
followingobservationalgradingat24,48and72 hpostapplicationof
the test chemical. The GHS was adopted in 2002 and published in
2003 (Silk, 2003).
Despite the adoption of the GHS, Draize testing is often
criticized due to its subjective and time consuming nature, lack of
repeatability, variable estimates, insufficient relevance of test
chemical application (Davila et al., 1998), high dosages (Curren and
Harbell, 2002) and over-prediction of human responses (Jester
et al., 2001), primarily due to interspecies differences. In addition,
for most routine and acute toxicity tests, for example skin toxicity
tests, there are standardized exposure times and/or delivery
methods in place. This is not the case with eye irritation; liquids,
pastes and solids all have different contact times with the eye, none
of which are well defined (Prinsen, 2006). Draize testing also fails
to elucidate the underpinning cellular and molecular mechanisms
of toxicology. Since Draize assessments are based upon penlight or
slit-lamp assessments, they provide very little information
regarding the primary or secondary responses in the cornea, iris
or conjunctiva (Maurer et al., 2002). Despite its “gold standard”
status, Draize testing was never formally validated to any
significant degree (Freeberg et al., 1986b). Since the anatomy of
the rabbit eye differs from the human eye structurally, physiologi-
cally and biochemically, differences in sensitivity to irritants can
occur. For example, in comparison to humans, rabbit corneas are
thinner, have lower tear production, blinking frequency and ocular
surface sensitivity (Huhtala et al., 2008). Rabbits have larger
conjunctival sacs and a nictitating membrane (third eyelid), which
may aid the removal of a test substance from the ocular surface
(Calabrese, 1987).
There is almost no other field of science in which the
fundamental experimental protocols have remained relatively
unchanged for more than 40 years (Hartung, 2009), and yet
consumers continually expect increased safety and information
regarding their products. Worldwide, approximately £10 billion is
spent on animal experimentation per annum, approximately
£2 billion of which is on toxicological studies (Hartung, 2009).
The cost associated with using, housing and maintaining colonies
of live animals for toxicology testing of a single compound can
exceed millions of pounds (Davila et al., 1998). Ethical (animal
welfare), business (time and cost), scientific advances (reproduc-
ibility, mechanistic understanding) and legal concerns have all
driven the demand for alternative, preferably animal-free testing
platforms and protocols which are more precise and relevant to
humans. There has been more focus on developing alternative
testing techniques to Draize than all other in vivo toxicity tests
combined (Huhtala et al., 2008). However, the development of
alternative models has not advanced in a steady or continuous
manner (Dholakiya and Barile, 2013), although the ban on animal
testing for cosmetics use (Regulation (EC) No.1223/2009) has acted
as a key driver for the development of alternative methods since
this sector is constantly having to provide innovative and safe
products. In Europe, with directive 2010/63/EU, there is a legal
requirement to use alternatives where they exist. However, the
reduction of animal use is primarily concentrated on toxicology
studies since no government agency to date has eliminated animal
use in basic biomedical research or pharmaceutical development.
3. Alternative in vivo tests
3.1. Low-volume eye-irritation test (LVET)
Low-volume eye-irritation tests (LVET) were developed in
response to a recommendation from the National Research Council(NRC, 1977). LVET is a refinement of Draize testing developed by
Griffith et al. (1980). The primary difference to the Draize test is that
lower volumes of test substances (0.01 ml/0.01 g) (Lambert et al.,
1993) are applied to the right-eye of the animal (Maurer et al., 2002),
with no forced eyelid closure employed (ICCVAM, 2010b). Test
substances are also only applied to the corneal surface and not the
conjunctival sac. The test is believed to be less stressful to the tested
animal (Jester et al., 2001). Pathological changes are characterized in
the cornea, conjunctiva and iris/cilliary body (Maurer et al., 2002).
Most LVET data is based upon surfactant-based mixtures or
responses that are associated with mild irritation or non-irritants.
This is due to the importance of surfactant use in cosmetic,
pharmaceutical and household cleaning products (Davila et al.,
1998). However, Gettings et al. (1996) investigated LVET in response
to severe irritants and reported an under-prediction of results when
compared to Draize data. Since Draize testing is often criticized for its
over-prediction of human responses, it is arguable that LVET testing
is more accurate (Freeberg et al., 1984, 1986a; Ghassemi et al., 1993;
Roggeband et al., 2000). However, LVET is still criticized for its use of
animals. In addition, should a negative irritancy result occur using a
lower test volume, the standard procedure is to increase the
concentration of thedrug,effectively resorting back toDraizetesting.
The Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) recently evaluated the validity
of LVET for the replacement of Draize testing. It was not considered
to be a valid replacement nor recommend for prospective ocular
safety testing (ICCVAM, 2010b). As a result, LVET has yet to be
adopted by any regulatory agency as an alternative test. The
reluctance to adopt LVET may be due to the fact that it does not
offer the element of “exaggeration” present in Draize testing,
that helps to assure public safety (Freeberg et al., 1986b; Ubels and
Clousing, 2005). However, retrospective LVET data is still useful to
weight-of-evidence approaches.
3.2. Human data
It has been suggested that the “gold standard” for eye irritation
should be the human response (Bagley et al., 2006) and that ideally,
a testing strategy to determine if a substance is harmful to humans
would utilize an extremely high number of human subjects in
order to faithfully represent human diversity. They would have to
be unknowingly exposed to a substance under realistic conditions
and the effects assessed (Hartung, 2009). However, such experi-
mentation is both unrealistic and unethical. As a result, human
study data and experiences of potential ocular hazards are only
available from either accidental exposure or clinical studies.
Unfortunately, accidental exposure data often does not realistically
represent the most severe lesions since exposure is often brief due
to immediate flushing of the eye. Furthermore, detailed studies by
ophthalmologists and emergency room clinicians are often not
collected or recorded. Clinical studies using undiluted products
raise both scientific and ethical concerns, so experiments have to
be carefully controlled. In clinical studies, the test material (often
very small volumes and/or diluted) is usually applied to the upper
or lower conjunctival sac, as opposed to the apex of the cornea as in
in vivo rabbit studies (Freeberg et al., 1986b). This in itself raises
concerns about the comparability of the outcomes. In addition,
human testing often investigates the “sting” more so than irritation
(Freeberg et al., 1986b). Studies performed in the 1980s compared
results from hundreds of accidental human exposures with Draize
and LVET tests (Freeberg et al., 1984, 1986a,b). In such a study using
human volunteers, household substances commonly associated
with accidental exposure (shampoo, hand soap, fabric softeners),
exposure data was collected under known, controlled conditions to
establish the relationship between in vivo animal tests and human
exposure effects (Freeberg et al., 1986b). It was demonstrated that
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exposure, whereas LVET correlated well, although still
over-predicted results.
Human studies are limited, and are usually comparing human
responses with Draize or LVET, as proof-of-principle that LVET is
more credible than Draize testing (Roggeband et al., 2000), and not
as a comparison for the validation of alternative methods. A
prevalent problem is that there is no human database for the
development of the prediction models needed in validation
studies, thus in vitro toxicity tests are still being compared to
rabbit data (Bagley et al., 2006).
4. Ex vivo tests
4.1. Isolated/enucleated organ/organotypic methods
Ocular organotypic models are isolated systems that aim to
maintain short-term normal physiological and biochemical function
of the enucleated eye or cornea (Barile, 2010). The test material is
often applied neat so is more relevant to industrial testing (Reader
et al., 1990) and more faithfully represents accidental exposure. The
protocols usually utilize opacitometric and spectroscopic methods
for quantitative assessment of changes to the isolated cornea in
response to a test material followed by histological analysis. Corneal
opacity is also an in vivo corneal endpoint, although the data is
observational, so often subjective. Corneal opacity acts as an
indicatorof proteindenaturation, swelling, vacuolation and damage
to the epithelium and corneal stroma (Barile, 2010). Fluorescein
retention/leakage of the cornea is often used as a measure of
permeability (Prinsen and Koëter,1993), although invivo the iris and
the conjunctiva are also involved in ocular irritation, so corneal
swelling and histological analysis are often included as additional
endpoints in organotypic models (OECD, 2009a), often to distin-
guish “borderline” cases. Unlike in vivo testing, the quantitative
assessment of corneal opacity and swelling provides more solid
data, allowing for inter-laboratory variations to be easily deter-
mined. These measurements are then combined to derive an eye
irritation classification or an in vitro irritancy score. Eye irritation is
primarily determined by the extent of initial injury that correlates
with the extent of cell death and ultimately the outcome of an
irritant on an eye (Jester et al., 2001). Generally, slight irritants
damage the superficial epithelium, mild irritants penetrate further
to damage the stroma and severe irritants penetrate through the
cornea and damage the endothelium (Jester et al., 2001) (Fig. 1).
Ocular organotypic models or enucleated eye tests (EET) were
first introducedby Burtonetal. (1981) usingisolatedrabbiteyes(IRE)
from animals used for other research purposes, or those that had
been sacrificed commercially as a food source (ICCVAM, 2010c). The
IRE test, or rabbit enucleated eye test (REET) was originallyFig. 1. Test substances that penetrate the furthest into the corneal tissue generally
cause the most severe irritation.developed to detect severe irritants that cause serious irreversible
eye damage (Guo et al., 2012). Currently, the most commonly used
test substances for IRE are active pharmaceutical ingredients,
chemical/synthetic intermediates, cleaners, raw materials, soaps
and detergents, solvents and surfactants (ICCVAM, 2010c).
Lab-specific IRE protocols have developed over time, with variables
including the evaluation of one to four different endpoints,
differences in prediction models or classification systems,
differences in the number of controls used and methodological
variations (ICCVAM, 2010c). IRE has been extensively evaluated by
international regulatory bodies including the European Commis-
sion/British Home Office (EC/HO), the Cosmetic, Toiletry and
Perfumery Association (CTPA) and the Interagency Regulatory
Alternatives Group (IRAG) (Guo et al., 2012). However, to date, the
IRE protocol is not considered to be adequately validated for
classification of ocular irritancy. Instead, it is advised that IRE is used
for non-regulatory optimization studies to facilitate the collection of
data to expand toxicology databases (ICCVAM, 2010c).
Slaughterhouse waste has been extensively investigated as an
alternative tissue source (Prinsen,1996) for EETs. Bovine or porcine
corneas are often used (Reichl and Muller-Goymann, 2001),
although chicken enucleated eye tests (CEET), also known as the
isolated chicken eye (ICE) test are widely accepted to be a reliable
and accurate slaughterhouse tissue for assessing the eye irritation
potential of test materials (Prinsen, 1996). The ICE testing protocol
(TG 438, (OECD, 2013b) is based upon the IRE model and was first
described by Prinsen and Koëter (1993). The eyes are isolated from
an intact chicken head and processed 2 h postmortem. The
enucleated eye is then positioned in a clamp, with the cornea
positioned vertically and transferred to a superfusion apparatus for
examination of damage (Maurer et al., 2002) (Fig. 2i). Once
approved, the eyes are equilibrated for up to 1 h (Fig. 2ii). Baseline
thickness and opacity measurements are then recorded, before the
eye is positioned horizontally and the test substance applied
(0.03 ml liquid, 0.03 g solid) for 10 s (Fig. 2iii). The cornea is then
rinsed with hypertonic saline (Fig. 2iv) before being returned to the
superfusion chamber for analysis (Fig. 2v). Toxic effects are
recorded by measuring changes in opacity, fluorescein retention,
tissue thickness (swelling) and a macroscopic evaluation of
changes to the surface of the tissue (OECD, 2013b).
A recent re-evaluation of ICE testing resulted in an endorsement
for the test as being scientifically sound and that the test can be
successfully used to identify substances that do not require
classification (non-irritants, GHS No Category) as well as those
deemed to cause serious irreversible eye damage (GHS Category 1).
This guidance was adopted in 2009 (OECD, 2009a) and updated in
2013 (OECD, 2013b). Solids (soluble and insoluble), liquids,
emulsions and gels can all be tested, although gases and aerosols
have yet to be assessed and validated using this method. When
used to identify GHS Category 1 chemicals, ICE has an overall
accuracy of 86%, when used to identify GHS No Category chemicals
ICE has an overall accuracy of 82% (OECD, 2013b). ICE is often used
as a pre-screen for Draize testing; although despite promising
outcomes the in vivo Draize testing results still overrule ex vivo
results should discrepancies occur. Discrepancies are often
associated with high false positive results for alcohols, and high
false negative results for solids, surfactants and anti-fouling
organic solvent containing paints (OECD, 2009a). ICE cannot be
used to classify GHS Category 2, 2A or 2B chemicals, although to
date, no ex vivo or in vitro test is capable of classifying chemicals in
this category.
The Bovine Cornea Opacity Permeability (BCOP) assay was first
developed by Gautheron et al. (1992) based on methods originally
described by Muir (1984, 1985, 1987) and Tchao (1988). The intact
corneas of healthy animals are held between O-rings mounted over
a (posterior) chamber; an anterior chamber is positioned above the
Fig. 2. Schematic representation of the chicken enucleated eye test (CEET), also known as the isolated chicken eye (ICE) protocol, which is based upon the isolated rabbit eye
(IRE) protocol.
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has its own dosing hole which allows both the epithelium and
endothelium to be treated independently. Currently, opacity is
measured using an OP-KIT opacitometer, which provides a center-
weighted reading of light transmission by measuring the changes
in voltage when the transmission of white light alters as it passes
through the cornea (Verstraelen et al., 2013). However, opacity
readings can be underestimated as opaque areas tend to develop inFig. 3. Testing chamber utilized in Bovine Cornea Opacity Permspots in a non-homogeneous manner around the corneal periphery
(Verstraelen et al., 2013). In response to this Van Goethem et al.
(2010) developed a prototype laser light based opacitometer
(PLLBOA), which has been further improved via the introduction of
a camera with a speckle noise reducer, and an optimization of
treatment conditions to more closely mimic the in vivo scenario
(Jamur and Oliver, 2010; Verstraelen et al., 2013). A minimum of
three eyes are used per test. Two different treatment protocols areeability (BCOP) and porcine cornea opacity (PCOP) testing.
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not. An advantage of this assay is its speed, with results usually
obtained within 24 h.
BCOP testing has been evaluated numerous times by ICCVAM, in
conjunction with the European Union reference laboratory for
alternatives to animal testing (EURL-ECVAM), formally known as
the European Centre for the Validation of Alternative Methods
(ECVAM) and the Japanese Centre for the Valuation of Alternative
Methods (JaCVAM) regarding its suitability in identifying both
substances that induce serious damage and those that are
classified as non-irritants. It has been determined that BCOP is
suitable and scientifically valid for both purposes (OECD, 2013a)
and is routinely used by cosmetics and drug development
companies for in-house testing of process intermediates (Eskes
et al., 2005). Although it cannot be considered as a stand-alone test,
BCOP received international acceptance in 2009 (OECD TG 437)
which was then reviewed and updated in 2013 (OECD, 2013a). It is
recommended for identifying severe irritants without further
testing (OECD, 2009b) and has received endorsement for being a
scientifically valid alternative test (OECD, 2013a). BCOP and has an
overall accuracy of 79% when used to classify GHS Category
1 irritants, when compared to Draize testing (OECD, 2009b, 2013a).
Loss of accuracy has been linked to high false positive rates for
alcohols, ketones and solid test materials. When these are
excluded, BCOP accuracy increases to 85%. However, since all
alcohols and ketones are not over-predicted, they are not
considered to be out of the applicability domain of the test. Solid
materials often result in variable data and irrelevant results when
using Draize testing (Prinsen, 2006) since solid materials can also
cause mechanical damage. With regards to the classification of test
materials that do not promote serious eye damage (GHS No
Category), BCOP has an overall accuracy of 69%. BCOP does have a
high false positive rate of 69% when compared to Draize data, but
this value, although seemingly high, is not critical, since non-
irritating chemicals which have a low in vitro irritancy score (IVIS)
will be tested using another adequately validated in vitro test data,
or as a last option in vivo rabbit testing (OECD, 2013a).
The porcine cornea opacity permeability (PCOP) assay uses
porcine corneas, which can be considered as advantageous in
comparison to bovine corneas since there are fewer concerns
regarding encephalopathy diseases (Van den Berghe et al., 2005).
Anatomically, it more accurately resembles the human cornea with
regards to structure and thickness, and porcine corneas have been
regularly used in ophthalmic research (Lynch and Ahearne, 2013).
Since corneal size is different between pigs and cows, the holder
utilized in PCOP studies has been slightly modified, with smaller
diameters, and reduced volumes of test substances (Van den
Berghe et al., 2005). Preliminary studies concerning PCOP revealed
that it can be used to accurately predict eye irritation for liquid andFig. 4. Schematic representation of the chorioallantoic membrane vascular assay (CAMV
CAM), or simply CAM assay.water soluble substances (Van den Berghe et al., 2005). However, it
has yet to be adopted by regulatory bodies that seem to favor BCOP.
Organotypic/enucleated models are borderline between in vivo
and in vitro systems and are advantageous in that they have fewer
ethical connotations (Luepke, 1985) with reduced costs. Although
promising results have been obtained from EETs they all share the
common problem that interspecies differences regarding anatomy
and physiology are still present. Such differences produce
discrepancies in permeation studies and toxicity tests (Reichl
et al., 2004; Reichl and Muller-Goymann, 2003). EET models also
lack, or do not consider conjunctival and irradial issues,
inflammatory response elements and corneal recovery or revers-
ibility of lesions (Guo et al., 2012). They also only account for
corneal effects and cannot predict systemic effects of substances,
such as the lethality of certain pesticides (OECD, 2009a).
Furthermore they can only be used for relatively short-term
assessment periods (4 h), and so are not suitable for testing
substances that produce effects over extended time frames.
However, such problems are associated with all ex vivo testing
methods and protocols.
4.2. Non-ocular organotypic models
The chorioallantoic membrane vascular assay (CAMVA), also
known as the Hen’s egg test (HET), or Hühner-embryonen test on
CAM (HET-CAM), or simply CAM assay was first proposed by Luepe
and Kemper (Luepke, 1985; Luepke and Kemper, 1986). CAM is the
vascularized respiratory membrane found within the membrane of
a fertilized chicken egg, with a vasculature and inflammatory
process similar to the conjunctival tissue of rabbit’s eyes. The test is
used to provide qualitative information on the potential effects
occurring in the conjunctiva following exposure to a substance,
whilst evaluation of coagulation can be used to reflect potential
corneal damage (NICEATM, 2006). Although CAM models are
usually classified alongside ICE, BCOP and IRE models, they differ in
evaluation criteria used (Barile, 2010) since they have the addition
of vasculature (Curren and Harbell, 2002). The general protocol
involves exposing the CAM (Fig. 4i), the application of the test
material to the surface (0.2–0.3 ml liquid, 0.1–0.3 g solid) (Fig. 4ii),
followed by rinsing (Fig. 4iii) and observation of changes to the
membrane morphology which are assessed and scored (Fig. 4iv).
Incubation times, relative humidity, number of replicates, breed of
hen (although white leghorn breed is most often used), criteria for
egg selection (age/weight), egg rotation, method of opening the
eggshell, volume/weight/concentration of test substance used
(although usually applied neat), use of positive/negative controls
and exposure times may vary dependent upon the protocol used.
This inadvertently leads to problems regarding intra-laboratory
reproducibility. Most protocols observe the time in secondsA), also known as the Hen’s egg test (HET), or Hühner-embryonen test on CAM (HET-
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coagulation that is measured, scored and then categorized
(Vinardell and Mitjans, 2008). Other endpoints include injection
(mild hemorrhage), vasoconstriction, dilation and lysis (disinte-
gration of vessels) (Gettings et al., 1996; Luepke, 1985; Luepke and
Kemper, 1986; Macian et al., 1996; Spielmann, 1995; Sterzel et al.,
1990). The irritation scoring varies dependent upon the classifica-
tion system being used. The use of colored, turbid or substances
that adhere to the CAM have been linked to compromised results
since they impair visualization (NICEATM, 2006). The CAM assay
has yet to receive international regulatory acceptance. Instead
ICCVAM (2010a) recommends that the test is used for
non-regulatory validation or optimization studies.
The slug mucosal irritation (SMI) assay was developed at the
laboratory of pharmaceutical toxicology, Ghent University,
Belgium to predict the mucosal irritancy potency of pharmaceuti-
cal formulations and ingredients (Adriaens et al., 2001, 2008;
Adriaens and Remon, 1999). It uses the terrestrial slug Arion
lusitanicus, which is considered to have limited sentience and so is
not protected by legislation covering animal experiments
(Adriaens and Remon, 1999). Slugs produce mucous and lose
body weight when placed upon irritating surfaces. When tissue
damage occurs the slug releases additional proteins and enzymes
from its mucosal surface. Both of these factors allow for
quantifiable endpoints, and for substances to be classified as
non-irritating, irritating or severely irritating. In general, mild
irritants cause an increase in mucous production, whereas severe
irritants result in tissue damage and protein/enzyme release in
addition to increased mucous production (Adriaens et al., 2008).
In a previous study using 20 known reference chemicals it was
shown that the SMI assay was a reliable and reproducible testing
system (Adriaens et al., 2008). However the SMI assay failed to pass
a formal validation study, so is currently only used as a pre-screen
for simple toxicological endpoints.
5. In vitro tests
In vitro toxicity testing models and assays using cultured cells
are advantageous compared to in vivo and ex vivo testing in that
they are relatively inexpensive, simple, and quick to manufacture.
This allows for replication and quantifiable data to be gathered,
whilst also lending itself to automation. In vitro systems may also
allow for a mechanistic understanding of toxicity at the cellular or
molecular level (Davila et al., 1998). They are also capable of
creating a broader range of toxicology testing capabilities such as
multiple endpoints, concentrations, exposure methods and times
to be better controlled and tailored accordingly.
One of the original alternative ocular irritation models was the
EYTEXTM system which was developed, tested and evaluated in the
1990s (Courtellemont et al., 1999; Gordon et al., 1990; Matsukawa
et al., 1999; Roy et al., 1994). Although EYTEXTM was unreliable at
predicting ocular irritancy, primarily due to the lack of an
appropriate prediction model; it did set the stage for the
development of ocular toxicity models. The Ocular Irritection1
assay is an updated protocol based upon the former EYTEXTM
system (Eskes et al., 2005, 2014). The test is based upon the
principle that eye irritation and corneal opacity caused by
exposure to irritating chemicals alter the fundamental function
of the proteins that make up the highly organized corneal tissue
(Eskes et al., 2005). The assay is available as an off-the-shelf kit
comprised of a macromolecular reagent of proteins, lipids, and low
molecular weight proteins which when rehydrated form an
ordered matrix similar to that of the native tissue, a membrane
disc which allows for delivery of the test chemical, instrumenta-
tion and computer software. Test chemicals are gradually added
using the defined membrane disc, resulting in turbidity of thematrix, due to the change in conformation and hydration (Eskes
et al., 2005). Spectroscopic methods are used to measure the
turbidity of the reagent at 405 nm. Prospective and retrospective
validation studies have been performed to evaluate the suitability
of the Ocular Irritection1 assay for discriminating between
chemicals that do not require classification from chemicals that
do (Eskes et al., 2014). Limitations include limited usefulness with
respect to intensely colored chemicals, underestimation of some
cationic surfactants and overestimation of surfactant based
formulations containing magnesium and multi-carboxylated
carbohydrate chemicals (Eskes et al., 2005). Currently, the results
of prospective and retrospective validation studies have been
submitted for formal validation (Eskes et al., 2014).
5.1. Cytotoxicity assessment
Most in vitro ocular toxicity assays consist of a monolayer of
cultured cells and a cytotoxicity assessment in response to a test
material. In general, cytotoxicity measurements are quick, simple
and inexpensive (Takahashi et al., 2008). Among the methods of
assessing cytotoxicity are thymidine incorporation, Coomassie
brilliant blue protein measurements, crystal violet and Lowry
reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assays (MTT assays), lactate dehydrogenase leakage
(LDH), fluorescein leakage (FL) trypan blue exclusion, florescent
staining with propidium iodide and neutral red uptake/release
tests (Huhtala et al., 2008). Each of these methods has their
advantages and limitations. In general, a combination of two or
more of these methods is normally used to assess cytotoxicity.
Several assays combine cell staining with fluorescence or
absorbance measurement to monitor changes in cell number and
determine whether a substance is cytotoxic. Assays that use dyes
such as trypan blue or propidium iodide are based on the concept
that these dyes will be prevented from entering the cell unless there
is disruption to the cells membrane (Strober, 2001). Hence healthy
cells will remain unstained, while dead cells will stain positive. The
amount of dye within a cell population can be measured and used to
determine the percentage of cytotoxic cells. One limitation with this
approach is that it only stains dead cells whilst dying or unhealthy
cells may remain unstained. Alternatively a dye such as crystal violet
can stain deoxyribonucleic acid (DNA) within a cell as shown (Fig. 5).
In this assay the color absorbance of the stained cells can be
measured at a wavelength of approximately 570 nm, which can then
be used to assess the number of cells present (Gillies et al., 1986;
Rothman, 1986). A reduction in cell number would indicate a
cytotoxic effect. In the neutral red assay, lysosomes rather than DNA
in healthy cells are stained positive. The dye can then be extracted
and used to quantify the number of viable cells (Repetto et al., 2008).
Fotakis and Timbrell (2006) found that the neutral red assay was
more sensitive to cytotoxic effects on cells than several other assays
tested.
In addition to staining, DNA can be quantified using other
techniques. For example in a thymidine incorporation assay,
3H-thymidine (a radioactive nucleoside) is incorporated into
newly synthesized DNA during mitosis. Inhabitation of thymidine
incorporation would indicate cytotoxicity.
Protein assays have been used to determine cytotoxicity by
measuring protein content within cells. A reduction in protein
concentration would correspond to a decrease in the number of
cells. Coomassie brilliant blue protein assays (also referred to as the
Bradford assay) is a colorimetric protein assay that can be used to
quantify cellular protein by measuring the color absorbance from
stained cells. Similarly, the Lowry test measures the amount of
cellular protein by reacting copper ions to amino acids in proteins
under alkaline conditions and measuring a subsequent color
change.
Fig. 5. Crystal violet staining of DNA in human adipose cell isolated from the vascular stromal fraction (scale bar 100 mm).
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cytotoxicity. LDH assays quantify the release of LDH following
rupture of the cell membrane by using it to catalyze the conversion
of lactate to pyruvate which can be measured colormetrically and
used to quantify cell death. MTT assays measures the reduction of
yellow MTT to purple formazan by mitochondrial succinate
dehydrogenase. This change in color is measurable via spectro-
photometry. As MTT reduction only occurs in metabolically active
cells, the spectrophotometer reading can give an estimate of the
number of viable cells present.
The short time exposure test (STE) is a relatively simple assay
method that estimates cell cytotoxicity and viability using MTT
(Kojima et al., 2013; Takahashi et al., 2008, 2011). It utilizes a
confluent monolayer of rabbit corneal cell lines (Statens Serumin-
stitut rabbit corneal, SIRC) on a 96 well polycarbonate microplate
(Takahashi et al., 2008). Test chemicals are dissolved or uniformly
distributed in either physiological saline, 5% dimethyl sulfoxide
(DMSO) in physiological saline, or mineral oils as test solvents, as
opposed to culture medium which is often used in cytotoxic tests.
This allows for water insoluble materials, acids and amides to be
evaluated (Takahashi et al., 2008), which would otherwise have
weakened effects when media is used as a solvent, due to the
buffering effect that the media may have. As the name suggests, the
exposure time to a given chemical is very short, it is only 5 min,
compared to longer exposure times used in the FL assay (15 min)
and the neutral red assay (1, 5 or 30 min) (Takahashi et al., 2008) for
example. It is believed that that the short exposure is more similar
to actual exposure conditions to a consumer product, whilst also
providing fast results (Kojima et al., 2013; Takahashi et al., 2011).
This also allows the STE to be used for high-throughput screening
to evaluate many chemicals. Two different concentrations of the
test material are evaluated, 5 and 0.5%, respectively. Post exposure
cell viability is compared to a solvent control (relative viability)
(OECD, 2014a; Takahashi et al., 2011). If the cell viability is 70% at
both 0.5 and 5% concentration, then the chemical is classified as
GHS Category 1. If cell viability if 70% at both concentrations then
the chemical is classified as GHS No Category (OECD, 2014a). The
STE was submitted to the OECD in 2011 as a method of high-
throughput screening (Kojima et al., 2013) to evaluate minimal,
moderate and severe eye irritation. The STE is currently under
investigation via the OECD for regulatory acceptance as part of a
tiered-testing strategy for either top–down or bottom–up
approaches. It is recommended that STE is used for the
identification of GHS Category 1, severe irritants and GHS No
Category, non-irritants, although in both instances further testing
is required to establish a definitive classification (OECD, 2014a). It
is not recommended for the identification of GHS Category 2 (A or
B) chemicals.Penetration of a dye or reagent through a barrier of cells is
another approach to assess cytotoxicity (Fig. 6). The FL assay (TG
460, (OECD, 2012c) can reveal the toxic effects of chemicals
following a short exposure. A monolayer of Madin–Darby canine
kidney (MDCK) cells are grown on permeable cell inserts. The test
works by measuring the amount of fluorescein leakage through the
cell monolayer which can be used to determine the integrity of the
barrier formed by the cells. Cytotoxicity would result in an increase
in the penetration of fluorescein through the monolayer. Increased
in vivo permeability of the corneal epithelium correlates with the
degree of inflammation and surface damage as eye irritation
occurs. The volume of fluorescin leakage is measured spectro-
fluorometrically and compared to controls. The FL20, which refers
to the concentration that causes 20% FL relative to an untreated
control is calculated and incorporated into a prediction model to
identify irritation. FL is recommended for use in identifying severe,
GHS Category 1 water soluble chemicals as part of a tiered-testing
strategy (OECD, 2012c). Any chemical that is not predicted as
severely irritating using FL would require further in vitro or in vivo
methods, since it is not capable of distinguishing such chemicals.
Another limitation is that FL cannot be used to classify strong acids
and bases, cell fixatives and highly volatile chemicals since their
modes of action cannot be measured using this mechanism. In
addition, viscous and colored materials are not suited to this test
(OECD, 2012c).
The Cytosensor Microphysiometer (CM) test method is a
cytometric and cell based assay which utilizes a sub-confluent
monolayer of mouse L3929 fibroblasts cultured on a transwell
insert in a sensor chamber. Changes in acidity in response to an
irritant are measured using a pH meter, ocular toxicity is
evaluated by calculating the reduction in metabolic rate caused
by the addition of a test chemical to the culture media
compared to the basal metabolic state. CM has been
recommended for the identification of GHS Category 1, severe
irritants and GHS non irritants (Alépée et al., 2013; OECD, 2012a).
The test is limited for use with test substances which do
not settle or separate during analysis, primarily water
soluble surfactants and surfactant-containing mixtures, but also
some non-water-soluble solids, viscous chemicals or suspensions
that maintain uniformity during analysis (OECD, 2012a). A draft
OECD test guidance for CM is currently under review (OECD,
2012a).
Cell cultures using both target cells and non-target cells, usually
expose cells to test materials that have been diluted in culture
media (Reader et al., 1990), although both water soluble and
insoluble materials can be assessed (Van Goethem et al., 2006). In
general, cell culture methods are based upon long term cell
survival, proliferation and function, including the release of
Fig. 6. Schematic diagram of the Fluorescein Leakage (FL) assay.
40 S.L. Wilson et al. / Toxicology 327 (2015) 32–46specific cytokines. Using permanent or immortalized cells lines is
advantageous with regards to availability, reproducibility, ease of
maintenance and ease of damage detection (Reader et al., 1990).
5.2. Corneal epithelial models
Several in vitro toxicity models have been developed using
corneal epithelial cells. In vivo the epithelium is the outermost layer
of the cornea that protects the underlying tissue by restricting
foreign material from entering while still allowing gas and nutrient
exchange to the underlying layers of the cornea. Thus it is the first
pointof contact for potentially hazardousmaterials. Invitrocultured
epithelium is capable of retaining the in vivo repair mechanisms
found in the native cornea (Davila et al., 1998), although these
mechanisms are not always given the level of attention they deserve
(Dholakiya and Barile, 2013). Epithelial models can be constructed
from animal cells (commonly SIRC cells (Ubels and Clousing, 2005))
such as in the STE test, human epidermal cells, or human corneal
cells, which are usually cultured in defined medium on cell culture
membranes using air-lifting techniques (Alépée et al., 2013; Cotovioet al., 2007; Kaluzhnyet al., 2011; Matsuda et al., 2009) to create a 3D
stratified epithelium. Cytotoxicity following topical exposure is
generally used as an endpoint (Curren and Harbell, 2002), and
epithelial models have the potential to identify non-classified/non-
irritating substances from mild irritants (Scott et al., 2010). Time-to-
toxicity measurements (ET50), which account for the time required
for a 50% reduction in cell or tissue viability following exposure
when compared to a negative control (Kaluzhny et al., 2011;
Osborne et al.,1995), are oftenused as an endpoint. Although human
primary epithelial cells have been investigated (Tripathi and
Tripathi, 1988, 1989; Tripathi et al., 1989), their use is limited in
toxicology models due to the lack of availability of human corneas
and difficulties associated with expanding and passaging primary
epithelial cells. Thus, rabbit corneal cells or mouse fibroblasts are
often utilized as an alternative source.
Matsuda et al. (2009) cultured rabbit corneal epithelium (RCE)
cells onto collagen hydrogels, which acts as a perabasal membrane.
To validate the model 30 chemicals with known degrees of eye
irritation (from Draize testing), ranging from non-irritating to
severely irritating were tested. Inconsistencies occurred when
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dilution, the volatility of the alcohol, or a reaction with the buffer
solution prior to testing (Matsuda et al., 2009).
The MatTek Corporation developed a commercially available 3D
corneal epithelial model (OCL-200) based upon human derived
epidermal keratinocytes from neonatal human foreskin (McLaugh-
lin et al., 2009; Sheasgreen et al., 2009) grown on cell-culture
inserts in serum-free media, to form a stratified, squamous
epithelium, marketed as EpiOcularTM. Test substances are directly
applied to the models, and cytotoxicity is measured using MTT.
Substances that cause the most rapid injury to cells generally have
higher irritation potentials (Matsuda et al., 2009). The original
protocol has since been developed into a single time-point protocol
known as the EpiOcularTM eye irritation test (EIT) (Pfannenbecker
et al., 2012). If the treated cells have viability greater than 60% post
treatment then the test substance is classified as non-irritating.
EpiOcularTM is currently used by numerous contract research
laboratories, industrial cosmetic, personal care, and household
chemical companies in place of Draize testing for product
development.
SkinEthic Laboratories (Nice, France) developed a standardized
3D reconstituted human corneal epithelium (HCE) model from
immortallized human corneal epithelial mucosa cells (Cotovio
et al., 2007; Doucet et al., 2006; Van Goethem et al., 2006), that is
structurally very similar to the corneal mucosa of the human eye.
Substances are tested using two different exposure times: (i) short
term, whereby the HCE is exposed to a chemical or substance for
10 min, (ii) long term, whereby the HCE is exposed for 60 min
followed by 16 h incubation. If the treated HCE has viability greater
than 50% post treatment then it is classified as non-irritating.
Both EpiOcularTM EIT and SkinEthicTM HCE models have
undergone prospective validation by EURL-ECVAM and Cosmetics
Europe todistinguish irritants (GHSClassification 1/Category2) from
non-irritants (GHS No Category) (Pfannenbecker et al., 2012; Zuang
et al., 2013). Over 100 chemicals were tested and both methods
showed high reproducibility (>90%) (Zuang et al., 2013). The
EpiOcularTM EIT met all the predictive capacity acceptance criteria
for thetestingof liquidsprotocol,but notallof thesecriteriaweremet
by the solids protocol nor by any of the SkinEthicTM HCE protocols
(Zuang et al., 2013). The EpiOcularTM EIT solids protocol was further
optimizedforsolidsandfurthervalidationwasconducted. At present
the SkinEthicTM HCE model is still undergoing further optimisation
for its solids protocol (Zuang et al., 2013). The final sensitivity of
EpiOcularTM EIT was determined to be 96%, with specificity of 63%
and accuracy of 80%, thus was considered valid for distinguishing
non-irritants from irritants (OECD, 2014a). However, EpiOcularTM
EIT is not intended to differentiate between GHS Category 1 (serious
eye damage) and GHS Category 2 (eye irritation). A draft test
guidance for EpiOcularTM EIT and performance standards has been
delivered to the OECD (2014a), and the final test guidelines are
expected to be adopted in 2015.
Recently Katoh et al. (2012, 2013) and Jung et al. (2011)
developed the LabCyte CORNEA-MODEL (Japanese Tissue Engi-
neering Co., Ltd., Japan) and MCTT-HCE model (MCTT, Seol, Korea),
respectively. Unlike the commercially available EpiOcularTM EIT
and SkinEthicTM HEC models, both utilize normal human corneal
epithelial cells isolated from the human limbus of remaining
corneal rim following transplantation that are cultured above and
supported by cell feeder layers. They have been shown to express
similar morphology and biomarker expression to the intact human
corneal epithelium. Pre-validation studies have been performed
for the LabCyte CORNEA-MODEL, to determine optimum treat-
ment time, volume, post-incubation time and rinsing protocols
(Jung et al., 2011). Although both MCTT-HCE and LabCyte CORNEA-
MODEL have reported promising results with a high degree of
accuracy, neither has yet to enter a formal validation assessment.One of the limitations with epithelial models is that the initial
enzymatic or mechanical dissociation of corneal tissue precluding
cellular isolation itself may evoke traumatic stimuli that result in a
diverse range of responses from the cell (Davila et al., 1998). This
may include the disruption of cellular structural integrity, the
release of inflammatory mediators or cell differentiation, all of
which can lead to differences between in vivo and in vitro
substance biokinetics (Davila et al., 1998). This needs to be
considered when using any cells for in vitro toxicology testing. The
use of immortalized epithelial cell lines does not always faithfully
represent corneal cell behavior in vivo, since the immortalization
process or subsequent culturing conditions alter expression
patterns. For instance, cell lines do not express cytokeratins (CK)
such as CK3, 7, 8, 18 and 19 (Huhtala et al., 2008). This may make
the identification of specific biomarkers of toxicology somewhat
more challenging.
Epithelial models are often fragile and have to be handled very
carefully to avoid drying and damaging the tissues. Cell detach-
ment in culture can lead to a misinterpretation of data dependent
upon the experimental endpoint (Davila et al., 1998). They are also
somewhat limited in that they only model the epithelial layer and
so cannot be used to determine the possible effects of substances
that in vivo penetrate the stroma and endothelium, or the
reversibility of the irritation. They also do not account for the
fact that some materials or chemicals may affect the various parts
of the eye differently (Reader et al., 1990) and that cell–cell
interactions, namely those between the epithelium and adjoining
stroma are pivotal to corneal responses (McLaughlin et al., 2009;
Wilson et al., 1999, 2014). In vitro cell based assays are also devoid
of hormonal, immune and neural influences. Although this makes
them simpler and easier to interpret, it can also be seen as a
limitation since it does not account for the interactions that occur
throughout the whole tissue, especially when considering the
complexity in an organ as specialized as the eye (Barile, 2010).
5.3. Corneal equivalents
In response to the limitations incurred from using in vitro
corneal epithelial models, more complex multicellular assays or
corneal equivalents, termed as such due to their similarity to real
corneas, have been under development in order to more accurately
replicate the complexity and inherent characteristics of the native
cornea. Both animal and human cells have been incorporated into
corneal equivalents. Many studies have attempted to culture
human primary cells under the premise that they will have a
greater capacity for determining human irritancy (Zieske et al.,
2004). However, problems associated with the isolation, growth,
maintenance and differentiation of corneal cells has meant that
many researchers choose to use transformed or immortalized
human cell lines or animal cells, since they are easier to culture.
Griffith et al. (1999) produced the first working equivalent of a
human cornea using immortalized human corneal cells. The model
was originally developed to help to understand why corneas fail to
heal properly after laser eye surgery. A collagen–chondroitin
sulfate substrate cross-linked with glutaraldehyde was used as a
tissue matrix. Initially a thin layer of endothelial cells was grown in
a culture dish. Keratocytes and support proteins were added before
finally adding the final epithelial layer. The gross morphology,
transparency and histology were reported to be similar to that of a
natural cornea. Tests performed using mild detergents determined
that the construct had a similar gene expression and wound-
healing response when compared to human eye-bank corneas,
albeit more sensitive. The stromal matrix was later modified to
allow for recovery mechanisms following exposure to chemical
treatments (Doillon et al., 2003), and this was later followed by the
introduction of nerve–target cell interactions (Suuronen et al.,
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utilized as a neural source, since optimal function, maintenance
and wound healing of many tissues is dependent to some extent on
peripheral sensory innervations (Suuronen et al., 2004). The
innervated corneal constructs were reported to have lower cell
death rates when exposed to test chemicals compared to non-
innervated equivalents. This suggests that the presence of nerves
protects the epithelium from chemical irritation and possibly
explains why previous non-innervated corneal models have been
deemed over-sensitive when used in toxicity studies. This model
still requires further development since many of the functional
properties of the nerves remain unclear. These types of models
may demonstrate more promise for clinical development as
cadaveric alternatives for corneal transplantation rather than as
models for toxicological testing.
Reichl et al. (2005) manufactured a human corneal equivalent
for in vitro drug permeation studies by culturing immortalized
epithelial, endothelial and stromal cells in a collagen hydrogel
matrix. Three reagents commonly used in ophthalmic drugs to
treat glaucoma and inflammatory diseases were tested and
permeation data obtained was compared with those from excised
porcine cornea and a porcine cornea construct (Reichl et al., 2004;
Reichl and Muller-Goymann, 2003). Porcine corneas were investi-
gated due to their relatively similar anatomy and physiology to the
human cornea. The human cornea construct had similar epithelial
barrier properties to a native cornea with only small ultrastructural
differences, possibly due to lack of tears and blinking. There was
increased permeability in the corneal equivalents compared to the
exercised porcine cornea for all reagents tested, although the
differences were relatively minor. Unfortunately there was no data
available to compare these corneal equivalents with an excised
human cornea (as in the studies by Griffith et al. (1999).
In general, in vitro models that include a stromal layer have the
greatest potential to distinguish severe/corrosive eye irritants from
other classes (Scott et al., 2010). However recent validation studies
have demonstrated that there is no single in vitro ocular irritation
test, combination of tests, or testing strategies capable of
completely replacing Draize testing (Huhtala et al., 2008) for
predicting the response of the full range of irritation classes. This is
partly due to a lack of understanding of the underlying cellular and
molecular mechanisms of eye irritation (Matsuda et al., 2009;
Maurer et al., 2002), a possible lack of innervation (Suuronen et al.,
2004), difficulties associated when comparing in vitro data with
historical animal data due to the subjective scoring systems used
and the fact that in vitro systems only partially model in vivo tests,
insufficient prediction models, inappropriate statistical analysis
(Eskes et al., 2005) and an apparent reluctance of regulatory bodies
to accept new in vitro corneal constructs.
The principle disadvantages of using multicellular in vitro
models for toxicity assays, is that like epithelial based assays, they
still lack the complexity of a complete organ (Becker et al., 2006).
For example, the composition of the aqueous humor and tear fluid,
or the mechanical stress of the eyelids and tear flow (Tegtmeyer
et al., 2001), intrinsic clearing mechanisms (tearing and blinking)
(Davila et al., 1998) are not taken into account. In a natural cornea
all of these factors are important to protect the eye and are
increased when exposed to irritation. In vitro false positive results
can be attributed to the continuous contact with a test compound
(Davila et al., 1998), thus the mechanisms that mimic tear
production and blinking may need to be incorporated into in vitro
toxicity models. Alternatively, in vitro assessment of the concen-
tration in which a test substance is pharmacologically or toxicology
active and relevant in vivo should be assessed (Davila et al., 1998)
since the extent of the initial response is a pivotal mechanistic
factor that determines the outcome of ocular irritation (Jester et al.,
2001; Maurer et al., 2002).5.4. Future of in vitro alternatives
It is unlikely that any single test, cell monolayer, three-
dimensional epithelium, or multicellular corneal equivalent will
be capable of mimicking the complexities and numerous physiolog-
ical parameters of an in vivo system following exposure to a given
substance (Borenfreund and Puerner, 1985; Pfannenbecker et al.,
2012). In fact, having a “one-size fits all” approach has largely been
abandoned, with the intention of many in vitro systems is to be
utilized as part of an integrated testing strategy using either
top–down or bottom–up tiered-testing approaches (Engelke et al.,
2013; Scott et al., 2010). Top–down approaches are for the
identification of severe irritants, bottom–up approaches are for
the identification of non-irritating substances (Barile, 2010; Engelke
et al., 2013). This results in two testing strategies to replace one in
vivo test and as of yet, neither strategy can be used to distinguish
between non-irritants and mild irritants and this remains an
on-going challenge (Barile, 2010; Nóbrega et al., 2012; Scott et al.,
2010). The commercial aims of in vitro testing are to be faster and
cheaper, although currently, the costs areroughlyonpar with Draize
testing. It is preferable that the testing procedures can be performed
without the need for specialist training or expensive equipment
(Dholakiya and Barile, 2013). From a corporate standpoint in vitro
tests require the same level of investment as they are currently
making using in vivo tests, so they either don't care, or fail to see the
benefits in switching. A large factor that affects the decision making
of corporate companies is that they are selling to a local market, not
just countries within the EU. For developing or newly industrialized
countries, Brazil, Russia, India, China and South Africa, the
underlying challenge is getting them to understand the roles of
invitro tests, which is a continuing educational challenge. In order to
overcome these issues, a re-evaluation of currently used in vitro
tests may be required (Nóbrega et al., 2012).
In vitro assays and models provide useful data that complement
in vivo studies allowing for significant reductions in the numbers of
animals used. In order realize this, it must be ensured that clear
endpoints correlate between in vivo and in vitro tests (Maurer et al.,
2002). In general, in vitro tests are validated against the Draize test
(Lenoir et al., 2011), with few actually investigating their
predictability compared to humans. Despite the lack of formal
validation, in vitro tests still are commonly used by industry. For
example, industrial toxicologists often use in vitro protocols for
prioritizing products and ingredients for further development
(Curren and Harbell, 2002). However, use of the Draize test is still
permitted worldwide, with the exception of the cosmetics section
within Europe. Although in vitro alternatives tests are available,
whether they are actually being used in practice is questionable.
Every country has its own regulations and data requirements. The
EU may be consolidated, but everywhere else is not and regulations
have to be negotiated one by one – this is a very slow process, with
no one country worse than the other. Regulations are aimed at
protecting humans, and regulators focus on this, the culture of
animal welfare is different in every country.
6. In silico models
In silico models are computer generated models that can play a
useful role in predicting the ocular toxicity of a substance. In silico
models utilize repositories of existing in vitro and in vivo toxicology
data to predict the toxicity of samples. Quantitative structure–
activity relationships (QSAR) are used to quantify the relationship
between a sample’s chemical structure and the biological effects
that result from the same chemical (Simon-Hettich et al., 2006).
QSAR is primarily based on the concept that the activity of
molecules can be predicted from their structure and that these
predictions are quantifiable (Valerio, 2011). The biological response
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generate predictive models. Once enough data for a specific
toxicological endpoint is collected, evaluated and weighted, then
a generalized relationship between the test substances and its
biological activity can be defined (Simon-Hettich et al., 2006).
Several different commercially available and freely available
modeling software packages have been developed, the applicability
of which have been previously evaluated in detail (Lo Piparo and
Worth, 2010). This type of modeling is also dependent on the
availability of suitable high quality databases, several of which have
been previously discussed (Valerio, 2009).
The primary advantages in using in silico models to predict
toxicity; other than the fact that they do not require the use of
animals or animal tissues; is their speed and relative low cost. In
vitro and in vivo toxicity models may take weeks or months to
generate results at considerable expense while in silico models can
generate results in minutes using just a computer and software.
The continuing increase in computer processing speeds over
recent years has enabled more sophisticated software to be
developed. Among the limitations associated with in silico models
are its reliance on high quality data. This can be a particular
problem when compiling data from different laboratories that may
have produced differing results. Since the models are reliant on
data generated using animal models and cell based assays, the
limitations associated with these, such as interspecies variations in
toxicological response, still exist. Other limitations with in silico
models have been described previously (Valerio, 2009). In general,
in silico models tend to be more useful in predicting a specific
endpoint rather than a broad range of toxicological effects that
may be produced from a test substance (Nigsch et al., 2009) and
they generally used with other test methods rather than
exclusively by themselves.
7. Regulation and validation of ocular toxicity testing
Finding suitable, regulatory approved and validated alterna-
tives to animal testing is a crucial aim of toxicological research
(Alépée et al., 2013) with regulatory bodies keen to adopt the use of
protocols that modify and reduce the number of animals used in
ocular testing procedures. For alternative methods to be success-
fully incorporated into safety assessment procedures, they need to
demonstrate that they can provide at least an equivalent or
preferably superior level of protection to that obtained with
current methods (Vinardell and Mitjans, 2008). In vitro and other
alternative testing methods have a long history in corporate
decision-making regarding chemical safety and product formula-
tion. However, for many years, alternative testing strategies were
neglected as a definitive testing strategy in the regulatory context
(Stephens and Mak, 2013). Thus, corporations would often
accompany alternative testing methods with more historical
animal-based methods (Stephens and Mak, 2013). In order to
move away from this status quo of toxicity testing, it is important
to have an understanding of regulatory testing requirements and
assessment and why they were developed (Fowle et al., 2013).
7.1. Regulation
Numerous regulatory authorities and systems exist worldwide
for the assessment and classification of potentially hazardous
substances. Their principal objective is to assess the hazardous
potential of substances that may come into contact with the eye in
order to supply regulations, guidelines and recommendations for
their safe use. This offers consumers or the end user protection via
the communication of hazardous information and protective
measures (ICCVAM, 2010b; Wilhelmus, 2001) to prevent misap-
plication and to minimize accidental exposure. Regulatoryassessment is based upon “informed decisions” that are not
purely scientific in nature. They have to take into account
congressional directives, legal precedent, benefit/cost
considerations and public values (Fowle et al., 2013). This
sometimes frustrates scientists, alternative-testing supporters
and stakeholders alike, since “good science” does not always drive
decision making (Fowle et al., 2013).
EURL-EVCAM aims to promote scientific and regulatory
acceptance of non-animal tests. Similarly, ICCVAM is an
interagency committee made up of 15 US Federal agencies
including the Consumer Product Safety Commission (CPSC),
National Institute for Occupational Safety and Health Administra-
tion (NIOSHA) and the FDA. ICCVAM aims to facilitate the
development, validation and regulatory acceptance of new and
revised regulatory test methods that reduce, refine and replace the
use of animals. It was originally developed as a committee of the
National Committee of Environmental Health Sciences (NIEHS) in
1997, and was made permanent in 2000 under NICEATM. Since
then ICCVAM has contributed to 63 alternative testing methods,
38 of which do not require live animals, although not all of them
are concerned with ocular tests.
Several directives restrict and even prohibit the use of animal
testing, for example the Amendment of the Cosmetic European
Directive (2003/15/EC) imposed a ban on the use of animals for the
testing of cosmetics and their ingredients. However, until recently
companies could still market products that had been animal tested
outside of the EU. A new cosmetic regulation replaced the
Cosmetics Directive in 2009 (Regulation (EC) No. 1223/2009)
and since July 2013, cosmetics and cosmetic ingredients tested on
animals can no longer be sold in Europe, even if they have
been tested elsewhere. This has promoted considerable
progress in replacing animal models for chemical toxicology
(Alépée et al., 2013).
7.2. Validation and regulatory acceptance
EURL-ECVAM (formally ECVAM) and ICCVAM were formed in
Europe and the US, respectively, to deal with the validation of
alternative testing methods (Vinardell and Mitjans, 2008).
Validation refers to the formal assessment, or rigorous set of
policies that challenge the specific objectives of a test method or
model with regard to its relevance and reliability. This in turn
provides the foundation to facilitate regulatory adoption and
acceptance (Corvi et al., 2006; Stephens and Mak, 2013). Relevance
refers to the extent to which a test or model correctly predicts/
measures the biological effect of interest; reliability is the degree to
which the data in the protocol is reproducible within the
guidelines or protocol of the method (Barile, 2010).
Most protocols undergo a pre-validation stage, designed to
prepare a test model or assay for further progression into a formal
validation study. These may involve intra-laboratory studies to
address protocol optimization (Phase I), transferability (Phase II)
and performance (Phase III) (Van Goethem et al., 2006), so that
prior agreements can be made on detailed protocols that prepares
and aids the test model or test in the formal validation process.
There are typically two types of validation study: prospective
and retrospective (Kandárová and Letašiová, 2011) and a combi-
nation of these approaches are usually applied in the formal
validation process (Hartung et al., 2004). Prospective studies
involve the generation of new data, whilst retrospective studies
re-assess existing data under standardized, controlled conditions.
ECVAM have proposed a modular validation assessment (Har-
tung et al., 2004), comprised of 7 modules aimed at determining the
performance characteristics, advantages and limitations of a model
or test for a specific purpose (Kandárová and Letašiová, 2011). The
modules are: (i) test definition, where the scientific objective of the
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standard operating procedures with clearly defined endpoints,
methods of results interpretation via prediction models and specific
controls used must be clearly defined; (ii) intra-laboratory
variability assessment, to determine potential variations in data
incurred due to different operators carrying out the protocol within
the same laboratory set-up. This assessment stage is usually not so
problematic, since laboratories developing a model or test would
usually abandon or modify an irreproducible protocol prior to
assessment submission (Ubels and Clousing, 2005); (iii) transfer-
ability, to demonstrate that the test can be repeated in different
laboratory set-ups. In the case of in silico models, this is the ability of
different operators to reproduce the model definition and
predictions, which is often dependent upon the strength of the
explanatory documentation provided; (iv) inter-laboratory vari-
ability, whereby three to four laboratories are typically asked to test
a defined numberof substances using the assessed method or model
to highlight discrepancies. This also adds further information to a
test's predictive capacity; (v) predictive capacity, which utilizes a
prediction model, to demonstrate how accurately a test can predict
toxicity compared to a reference test (i.e., Draize testing). Usually a
defined number of substances in at least three different laboratories
are assessed. Ironically, this stage of assessment can be hindered by
the low reliability of Draize testing (Ubels and Clousing, 2005); (vi)
applicability domain, which involves defining the purpose to which
a test can be applied including endpoints, chemical classes, test
material and physiochemical properties; (vii) performance stand-
ards, these need to be established for each test. However, if a similar,
previously validated method or model exists, then the validation
process is much faster (Hartung et al., 2004). The assessment of each
module is led by a validation management group (VMP), who will
then make recommendations to either ensue to peer review with a
completed dossier of the information, or to collect additional data
(IHCP, 2013). A test cannot proceed to peer review without a VMG
recommendation. A formal regulatory validation can take more
than five years to achieve (Sheasgreen et al., 2009) and may only
then be considered for regulatory acceptance once achieved.
Regulatory acceptance is a formal recognition that indicates a
test method or model may be used for a specific purpose.
Acceptance is usually followed by a formal adoption by the EU and
the OECD, and inclusion into the EU test method regulations and a
publically available OECD test guideline (IHCP, 2013). The OECD
continuously updates existing test guidelines and restructures
draft proposals for future adoption (Barile, 2010), to encourage
industries to use updated validated tests, whilst submitting data
based upon them (Stephens and Mak, 2013).
Most assessments of validation and regulatory acceptance have
occurred since 2000, following the establishment of vital alternative
testing centers and the drive initiated European Cosmetic Directive
(Stephens and Mak, 2013). However, the lack of human data has
arguably led to delays in establishing the validity of alternative tests
(Freeberg et al., 1986b). Currently only a limited number of ocular
toxicity assays have undergone validation and regulatory accep-
tance. BCOP, ICE and FL have been accepted by ICCVAM, EURL-
ECVAM and OECD for testing ocular corrosion and severe irritation.
CM has also been accepted but is still awaiting final publication of
OECD test guidelines. Dholakiya and Barile (2013) summarized the
validation status of several in vitro ocular toxicity assays. Since that
time a number of changes have been made to the validation status of
these tests.Forexample, updatedguidelines havebeen issued bythe
OECD for the BCOP (OECD, 2013b) and ICE tests (OECD, 2013a). For
both tests changes have been made concerning the identification of
chemical that do not require classification to UN GHS. In addition,
clarifications have been provided on the applicability of BCOP for
testing alcohols, ketones and solids and an updated list of chemicals
to be used to demonstrate technical proficiency when applying theICE test. A recent report by EURL-ECVAM on alternative methods
(Zuang et al., 2013) also provided an update on the regulatory
validation of several in vitro assays. To date EpiOcular EIT has passed
initial validation studies (Zuang et al., 2013) and guidelines are
currently being drafted by the OECD (2014b). The HET and IRE have
been rejected by ICCVAM while the EURL-ECVAM has requested
further optimization of the test protocol.
8. Conclusion
We have presented an overview of current practices in ocular
toxicity testing. While progress has been made in developing a
range of alternative techniques to in vivo testing, further progress is
required to reduce the dependency of toxicity testing on live
animals. Among the issues that need to be addressed by regulatory
bodies is whether Draize testing should still be considered as the
“gold standard” and whether results obtained from such testing
used to validate or evaluate alternative tests. In order to advance
alternative testing methodologies, there needs to be active
engagement and dialog between scientific and regulatory
communities.
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